Member Info for chester18

West Coast have brought in two high level specialist’s to help prove up and devise strategies for Elizabeth Hills.

This decision must be based on solid evidence that the amounts of silver are there to create a working mine. They are not messing about .

Another point of view. Why would the MM’s take on 2.5million shares at 9.519p ?

If they had a great distaste for Scancell shares why take on such a big lump at such an attractive price to the seller ?

Either they have someone else lined up or it’s another of these ‘moving stock’ between investments, procedure's.

This close to an AGM is manna from heaven for them to stir up the perceived market in Scancell’s stock.

Yes it’s always confusing because if we said it was a Sell, why would that volume not drag the price down to, let’s say 9.2p ?

MM’s special magic 😁

Sorry Rob

I that post I should have said ‘buy’….

Where could the MM’s have got the shares from to fulfil that trade if it was in fact a buy ?

Hi Rob

Just looking back over the last week of trading using only the LSE figures, I cannot see how the MM’s could have accumulated that much stock under 9.5p.

I’m not arguing against that it’s a sell using today’s price movements, only trying to understand where the MM’s accrued that many shares to be in a position to action that sell.

Isn’t he the American guy who interviewed Prof Lindy Durrant a couple of years back ?

I couldn’t make it last year but I’m confident that I will make the trip next week.

We have invested so much energy in discussing the subject matter for the last 10 years it’s only natural to want to see the whites of their eyes 😂😂

Also, let’s remember that the Modi1 update was promised for ‘Mid-year’ and then in a presentation it was Q3. So even though it’s been pushed back there was an expectation that enough data would be gathered for a much earlier release.

SCOPE news will definitely not arrive before the end of November and hopefully include news of a partnership deal.

GlyMabs could be positive if GenMab have finally moved to a Ph1.

Modi1 is a prime candidate for news in the next week.

It would certainly make the AGM very popular.

🤞🤞🤞

Thanks for your speculations.

The AGM can be very dry if there isn’t a clear ‘positive’ to talk about.

If there is absolutely no news then what can they say at the Presentation after the official business part of the AGM.

GlyMab Theraputics Ltd - Too Early to say what is happening there.

SCOPE Trial - Awaiting more data from Cohort3 and pressing on with Cohort4. Hoping to have data by end December.

Modi1 plus CPI’s in RCC - data accruing and hopefully there will be an update before year end.

Any questions - ‘ Yes, What time is the next bus to Victoria train Station”

A bit tongue in cheek but you get my point.

There is always a chance of some good news prior to an AGM. What are the pros and cons of having the Modi 1 plus checkpoints update before next Thursday ?

Unless you use Hellman’s mayonnaise 🤣

At the recent ‘SCOPE Trial Update’ it was stressed many times that Scancell now have very strong selection parameters for the Phase3 Reg Trial enrolment.

If a patient passes the criteria they will be highly likely to respond positively to SCIB1 plus double checkpoints.

The proof will be in the data but our CEO was confident that running a trial with such a specific enrolment markers can only lead to a positive and successful outcome.

Fantastic results but this is another individually targeted Vaccine.

"Designed with our AI-Immunology™ platform, EVX-01 and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient's immune system to fight off cancer by mounting a targeted response against tumors".

In summary, slightly better outcomes than 'Scib1 plus double checkpoint' but many times the cost.

It will soon be Scancell's time to shine 👍👍

Icecool

Companies do internal stock checks once or usually twice per year.

Physical inventory is matched against the figures in the computer system. It is total incompetence to gain $3.1 million dollars of stock and not investigate.

A well run accredited company has good stock controls and deals with ‘out of date’, ‘contaminated’ or ‘end of line products’.

By valuing product that cannot ever be sold or by not allocating the correct stock value always becomes flagged up during a thorough stock check.

I find it difficult to believe this is totally down to a system or administration errors.

The future actions taken or not taken against former employees will say if it was coerced or incompetence.

Morning Icecool

The over stating of profitability by not allocating know cost of sales is manipulation. Taking a very negative end of year 2024 from showing a $1m loss to an extremely positive profit of $1.9m.

This act meant that the CEO could claim all was well. How this over stating profits came about we do not know but it means the company is resetting from a much deeper financial / revenue negative.

The next 12 months will be brutal and needs strong leadership and a refocus on product accreditation through trial data.

It's fantastic to hear at least one person is benefiting from the addition of Modi1 to their cancer treatment.

My hope is that this positive story is being replicated many times within that Renal Cell cohort.

It would be such a welcome relief to finally have the proof that Moditope is showing what an incredible immunology breakthrough we all hoped it would be.

Fingers crossed that when this early data is released that we have somewhere near 24 patients all showing the same kind of healing.

ATB

Icecool

Thank you for your input to my question.

One thing we still need to move passed is the under reporting of the cost of sales. Hopefully it’s an admin issue with not a huge impact on past reported profits.

The sooner that is dealt with the sooner we’ll begin to see sentiment move back to positive.

Having said that, I still feel the drop is way too much given the size of the company and its potential future revenue’s.

Something that doesn’t make much sense to me is how the share price has plummeted to ‘below’ bargain basement levels.

Firstly, I just want to point out that TRX is still supplying its customers and still has products that are unique and IP protected.

The main surprise is the current Market Capitalisation of $7.36m which is way below the value of the companies actual operating value.

Debt is a necessary evil for a developing business and there are genuine concerns that current revenues need to be higher to cover the current levels of debt.

However looking at current Assets TRX does have a lot of fuel in the tank.

Inventory ( stock ) $16.7m

Receivables. $ 4.1m

Cash. $ 1.0m

Intangible Assets. $ 16.3m

Property, Plant & Equipment. $ 8.0m

Total Assets in the accounts. $ 47.0m

So why this share has fallen so low is a mystery and quite probably a huge over reaction considering what they do, what they actually own ( $8.0m of Property, Plant and Equipment ) and the potential size the their market.

Dracula1

The mantra for years now has been ‘Data, Data, Data’ and we are getting very close to some of that high end data.

Scancell’s three pronged attack has to show Large Pharma that at least one part is going to be commercially successful.

GenMab is interested in our Mabs but currently seems to be more engaged with other companies and other technology but could change very rapidly.

The SCOPE trial needs to gain a partner to help cover the cost of the Phase3 ‘Reg’ trial which will also bolster confidence in all Scancell’s technologies.

The wild card is the Modify trial. Up to this point the trial data has been progressive, very safe and shown that it has some benefits as a Mono therapy in stage 4 solid tumours.

Tested with a single checkpoint it has shown potential in Head and Neck cancers.

What we now await is how effective is Modi1 when combined with double checkpoints.

As I’ve said Moditope is the Wild Card because if this coming data in Renal Cell Carcinoma is good or very good it will be a huge breakthrough in fighting these late stage solid tumours and will definitely command the attention from some very large companies.

So hold on in there Drac1 because as I see it we are now in a time frame of weeks not years or months.

Could this be the ‘Diggle Share Hoover’ collecting more 10p shares. It would not surprise me if it is.